



Divi's Laboratories Limited

August 06, 2025

To
The Secretary
National Stock Exchange of India Limited
Exchange Plaza,
Bandra-Kurla Complex, Bandra (East)
Mumbai – 400 051

To
The Secretary
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street
Mumbai – 400 001

Trading Symbol: **DIVISLAB**

Scrip Code: **532488**

Dear Sir / Madam,

Sub: Outcome of Board Meeting held on August 06, 2025

Ref: Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015

Further to our letter dated July 26, 2025, we would like to inform that the Board of Directors of the Company at its meeting held on August 06, 2025, has approved unaudited financial results for the quarter ended June 30, 2025.

In terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, we are enclosing herewith the following:

1. Statement of unaudited standalone financial results for the quarter ended June 30, 2025, and Limited Review Report of the Statutory Auditors thereon.
2. Statement of unaudited consolidated financial results for the quarter ended June 30, 2025, and Limited Review Report of the Statutory Auditors thereon.
3. Press release on financial results.

The Board meeting commenced at 10.20 Hrs and concluded at 11.35 Hrs.

This is for your information and records.

Thanking you,
Yours faithfully,
For Divi's Laboratories Limited

M. Satish Choudhury
Company Secretary & Compliance Officer

DIVI'S LABORATORIES LIMITED

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th JUNE, 2025

(₹ in Crores)

S. No.	Particulars	Quarter ended			Year ended
		30.06.2025	31.03.2025	30.06.2024	31.03.2025
		(Unaudited)	(Audited)**	(Unaudited)	(Audited)
1	Income				
	Revenue from operations	2357	2536	2063	9198
	Other income	119	87	79	352
	Total income	2476	2623	2142	9550
2	Expenses				
	a) Cost of materials consumed	989	910	882	3760
	b) Purchases of stock-in-trade	-	-	-	-
	c) Changes in inventories of finished goods, work-in-progress, and stock-in-trade	(72)	59	(56)	(83)
	d) Employee benefits expense	330	341	285	1210
	e) Depreciation and amortization expense	112	107	97	401
	f) Finance costs	3	.*	.*	1
	g) Other expenses	367	345	331	1332
	Total expenses	1729	1762	1539	6621
3	Profit before exceptional items and tax (1-2)	747	861	603	2929
4	Exceptional items	-	-	-	-
5	Profit before tax (3-4)	747	861	603	2929
6	Tax expense				
	a) Current tax	191	225	178	793
	b) Deferred tax	(1)	(31)	(5)	(73)
	Total tax expense	190	194	173	720
7	Profit for the period (5-6)	557	667	430	2209
8	Other comprehensive income:				
	Items that will not be reclassified to Profit or Loss:				
	(i) Gain/(Loss) on Remeasurement of post-employment benefit obligation	(1)	(1)	(1)	(3)
	(ii) Income tax relating to the above	.*	.*	.*	1
	Total other comprehensive income (i+ii)	(1)	(1)	(1)	(2)
9	Total comprehensive income(7+8)	556	666	429	2207
10	Paid-up Equity Share Capital	53	53	53	53
11	Other equity excluding revaluation reserve				14842
12	Earnings per Share #				
	(Face Value Rs.2/- each) (not annualized)				
	a) Basic (Rs.)	20.95	25.12	16.18	83.20
	b) Diluted (Rs.)	20.95	25.12	16.18	83.20

Earnings per share calculated on actual amount of profit after tax in rupees

*Amount is below the rounding off norms adopted by the company.

Notes:

- The above Statement of Standalone Unaudited Financial Results for the quarter ended 30th June 2025 ("Standalone statement") is prepared in accordance with the recognition and measurement principles laid down in applicable Indian Accounting Standards, prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended. The Standalone statement has been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on August 06, 2025. The statutory auditors have carried out a limited review of the Standalone statement and issued an unmodified report thereon.
- The Company is engaged in the manufacture of Active Pharmaceutical Ingredients, Intermediates and Nutraceutical Ingredients and the same constitutes a single reportable business segment as per Ind AS 108.
- The Company does not have any discontinued operations and the profit for the period represents profits from continuing operations only.
- **Financial results for the quarter ended 31.03.2025 are the balancing figures between audited figures in respect of full financial year and the unaudited published year to date figures up to the third quarter of the respective financial year, which were subjected to limited review.
- Details of Forex gain/(loss) are as given below: (₹ in Crores)

	Quarter Ended			Year Ended
	30.06.2025	31.03.2025	30.06.2024	31.03.2025
Forex gain/(loss)	39	11	(1)	48

Forex gain has been included in other income and loss has been included in other expenses.

Place: Hyderabad
Date: August 06, 2025

For Divi's Laboratories Limited

Kiran S Divi

Dr. Kiran S Divi
Whole-time Director and Chief Executive Officer



Price Waterhouse Chartered Accountants LLP

Review Report

To
The Board of Directors
M/s Divi's Laboratories Limited
Divis Towers, 1-72/23(P)/303,
Cyber Hills, Gachibowli,
Hyderabad, 500032

1. We have reviewed the standalone unaudited financial results of Divi's Laboratories Limited (the "Company") for the quarter ended June 30, 2025, which are included in the accompanying "Statement of Standalone Unaudited Financial Results for the quarter ended June 30, 2025" (the "Standalone Statement"). The Standalone Statement has been prepared by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations, 2015"), which has been initialled by us for identification purposes. This Standalone Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Standalone Statement based on our review.
2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Standalone Statement is free of material misstatement.
3. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Standalone Statement has not been prepared in all material respects in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India and has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Price Waterhouse Chartered Accountants LLP
Firm Registration Number: 012754N/N500016



N.K. Varadarajan
Partner

Membership Number: 90196
UDIN: 25090196BMRJSL3448

Place: Hyderabad
Date: August 06, 2025

Price Waterhouse Chartered Accountants LLP, Unit - 2B, 8th Floor, Octave Block, Block E1, Parcel - 4, Salarpuria
Sattva Knowledge City, Raidurg, Hyderabad, Telangana - 500081
T: +91 (40) 44246740

Registered office and Head office: 11-A, Vishnu Digamber Marg, Sucheta Bhawan, New Delhi - 110002

Price Waterhouse (a Partnership Firm) converted into Price Waterhouse Chartered Accountants LLP (a Limited Liability Partnership with LLP identity no: LLPIN AAC-5001) with effect from July 25, 2014. Post its conversion to Price Waterhouse Chartered Accountants LLP, its ICAI registration number is 012754N/N500016 (ICAI registration number before conversion was 012754N)

DIVI'S LABORATORIES LIMITED

STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th JUNE 2025


(₹ in Crores)

S. No	Particulars	Quarter ended			Year ended
		30.06.2025 (Unaudited)	31.03.2025 (Audited)**	30.06.2024 (Unaudited)	31.03.2025 (Audited)
1	Income				
	Revenue from operations	2410	2585	2118	9360
	Other income	119	86	79	352
	Total income	2529	2671	2197	9712
2	Expenses				
	a) Cost of materials consumed	1010	931	893	3821
	b) Purchases of stock-in-trade	-	-	-	-
	c) Changes in inventories of finished goods, work-in- progress and stock-in-trade	(54)	50	(40)	(96)
	d) Employee benefits expense	340	350	292	1243
	e) Depreciation and amortization expense	112	107	97	402
	f) Finance costs	3	1	-*	2
	g) Other expenses	385	368	351	1424
	Total expenses	1796	1807	1593	6796
3	Profit before exceptional items and tax (1-2)	733	864	604	2916
4	Exceptional items	-	-	-	-
5	Profit before tax (3-4)	733	864	604	2916
6	Tax expense				
	a) Current tax	191	228	179	799
	b) Deferred tax	(3)	(26)	(5)	(74)
	Total tax expense	188	202	174	725
7	Profit for the period (5-6)	545	662	430	2191
8	Profit for the period attributable to:				
	Shareholders of the Company	545	662	430	2191
	Non-controlling interest	-	-	-	-
9	Other comprehensive income:				
	a) Items that will not be reclassified to profit or loss:				
	i) Gain on Remeasurement of post-employment benefit obligations	(1)	(1)	(1)	(3)
	ii) Income tax relating to the above	-*	-*	-*	1
	b) Items that will be reclassified to Profit or Loss:				
	i) Gain on exchange differences in translating the financial statements of foreign operations	4	1	2	6
	ii) Income tax relating to the above	-*	-*	-*	(1)
	Total other comprehensive income	3	-	1	3
10	Total other comprehensive income for the period attributable to:				
	Shareholders of the company	3	-	1	3
	Non-controlling interest	-	-	-	-
11	Total comprehensive income for the period (7+9)	548	662	431	2194
12	Total comprehensive income for the period attributable to:				
	Shareholders of the company	548	662	431	2194
	Non-controlling interest	-	-	-	-
13	Paid-up Equity Share Capital	53	53	53	53
14	Other Equity excluding revaluation reserves				14916
15	Earnings per Share #				
	(of Rs.2/- each) (not annualized)				
	a) Basic (Rs.)	20.49	24.93	16.20	82.53
	b) Diluted (Rs.)	20.49	24.93	16.20	82.53

Contd...

Earnings per share calculated on actual amount of profit after tax in rupees

* Amount is below the rounding off norms adopted by the group.



NOTES:

1. The above Statement of Consolidated Unaudited Financial Results for the quarter ended 30th June, 2025 ("Consolidated statement") is prepared in accordance with the recognition and measurement principles laid down in applicable Indian Accounting Standards, prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended. The Consolidated statement has been reviewed by the Audit Committee and approved by the Board of Directors of the Company at its meeting held on August 06, 2025. The statutory auditors have carried out a limited review of the Consolidated statement and issued an unmodified report thereon.
2. The consolidated financial results include the financial results of Divi's Laboratories Limited and its wholly owned subsidiaries Divis Laboratories (USA) Inc. and Divi's Laboratories Europe AG (Referred as the "Group").
3. The Group is engaged in the manufacture of Active Pharmaceutical Ingredients, Intermediates and Nutraceutical Ingredients and the same constitutes a single reporting business segment as per Ind AS 108.
4. The Group does not have any discontinued operations and the profit for the period represents the profits from continuing operations only.
5. **Financial results for the quarter ended 31.03.2025 are the balancing figures between audited figures in respect of full financial year and the unaudited published year to date figures up to the third quarter of the respective financial year, which were subjected to limited review.
6. Details of Forex gain/(loss) are as given below:

(₹ in Crores)

	Quarter Ended			Year Ended
	30.06.2025	31.03.2025	30.06.2024	31.03.2025
Forex gain/(loss)	39	10	(1)	48

Forex gain has been included in other income and loss has been included in other expenses.



Place: Hyderabad
Date: August 06, 2025

For Divi's Laboratories Limited

Kiran S Divi
Dr. Kiran S Divi

Whole-time Director and Chief Executive Officer




Price Waterhouse Chartered Accountants LLP

Review Report

To
The Board of Directors
M/s Divi's Laboratories Limited
Divis Towers, 1-72/23(P)/303,
Cyber Hills, Gachibowli,
Hyderabad, 500032

1. We have reviewed the consolidated unaudited financial results of Divi's Laboratories Limited (the "Parent") and its subsidiaries (the parent and its subsidiaries hereinafter referred to as the "Group"), [(refer Note 2 on the Consolidated Statement)] for the quarter ended June 30, 2025, which are included in the accompanying "Statement of Consolidated Unaudited Financial Results for the quarter ended June 30, 2025" (the "Consolidated Statement"). The Consolidated Statement is being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations"), which has been initialled by us for identification purposes.
2. This Consolidated Statement, which is the responsibility of the Parent's Management and has been approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Consolidated Statement based on our review.
3. We conducted our review of the Consolidated Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Consolidated Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.
4. The Consolidated Statement includes the results of the following entities:
 - a) Divis Laboratories (USA) Inc.
 - b) Divi's Laboratories Europe AG



Price Waterhouse Chartered Accountants LLP, Unit - 2B, 8th Floor, Octave Block, Block E1, Parcel - 4, Salarpuria
Sattva Knowledge City, Raidurg, Hyderabad, Telangana - 500081
T: +91 (40) 44246740

Registered office and Head office: 11-A, Vishnu Digamber Marg, Sucheta Bhawan, New Delhi - 110002

Price Waterhouse (a Partnership Firm) converted into Price Waterhouse Chartered Accountants LLP (a Limited Liability Partnership with LLP identity no: LLPIN AAC-5001) with effect from July 25, 2014. Post its conversion to Price Waterhouse Chartered Accountants LLP, its ICAI registration number is 012754N/N500016 (ICAI registration number before conversion was 012754N)

Price Waterhouse Chartered Accountants LLP

5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Consolidated Statement has not been prepared in all material respects in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India and has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. The consolidated unaudited financial results includes the interim financial information/ financial results of 2 subsidiaries which have not been reviewed by their auditors, whose interim financial information/ financial results reflect total revenue of Rs. 203 crores, total net loss after tax of Rs. 2 crores and total comprehensive income of Rs. 1 crore for the quarter ended June 30, 2025, as considered in the consolidated unaudited financial results. According to the information and explanations given to us by the Management, these interim financial information / financial results are not material to the Group.

Our conclusion on the Consolidated Statement is not modified in respect of the above matter.

For Price Waterhouse Chartered Accountants LLP
Firm Registration Number: 012754N/N500016



N.K. Varadarajan
Partner

Membership Number: 90196

UDIN: 25090196 BMRJS M2694

Place: Hyderabad
Date: August 06, 2025



DIVI'S LABORATORIES LIMITED

CIN: L24110TG1990PLC011854

Registered Office: 1-72/23(P)/DIVIS/303, Cyber Hills, Gachibowli, Hyderabad - 500 032, Telangana, India, Phone: +91 40 66966300, email: cs@divislabs.com, website: www.divislabs.com

PRESS RELEASE DATED AUGUST 06, 2025

Divi's Labs earns a Consolidated Total Income of ₹2,529 crores for Q1 of FY2025-26

Consolidated Financial Results

Divi's Laboratories has earned a consolidated total income ₹2,529 crores for the 1st quarter of the financial year 2025-26 as against a consolidated total income of ₹2,197 crores for the corresponding quarter of previous financial year.

Profit before Tax (PBT) for the current quarter amounted to ₹733 crores as against a PBT of ₹604 crores for the corresponding quarter of previous financial year and a PBT of ₹864 crores for the 4th quarter of previous financial year. The Company earned a Profit after Tax (PAT) of ₹545 crores for the current quarter as against a PAT of ₹430 crores for the corresponding quarter of the previous financial year. PAT for the 4th quarter of previous financial year was ₹662 crores.

Forex gain for the current quarter amounted to ₹39 crores as against a loss of ₹1 crore for the corresponding quarter of previous financial year.

Standalone Financial Results

On a standalone basis, the Company's earnings are given below:

Particulars	(₹ in crores)	
	For the Quarter ended	
	30.06.2025	30.06.2024
Total Income	2,476	2,142
PBT	747	603
Tax Expense	190	173
PAT	557	430

Kan Di

